Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502048 | 0.81 | CYP1A2 (0.57) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL13372873 | 0.78 | ADORA2A (0.36) | CYP1A2KDM4EGPR3MAPTLMNA | |
| SCHEMBL14099190 | 0.75 | CYP1A2 (0.53) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL30198446 | 0.74 | CYP1A2 (0.60) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL1672650 | 0.74 | CYP1A2 (0.60) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL30527184 | 0.74 | CYP1A2 (0.60) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL14941820 | 0.73 | RAB9A (0.43) | CYP1A2KDM4EMAPTNPC1LMNA | |
| SCHEMBL28424348 | 0.73 | CYP1A2 (0.61) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL13649235 | 0.73 | CYP1A2 (0.61) | CYP1A2KDM4EGPR3MAPTNPC1 | |
| SCHEMBL4510544 | 0.72 | ADORA3 (0.45) | CYP1A2KDM4EGPR3MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| US-9434698-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9345702-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160106849-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8889675-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011051950-A1 | 9-AMINOACRIDINE DERIVATIVES, THEIR PREPARATION AND USES | ARIEL-UNIVERSITY RESEARCH AND DEVELOPMENT COMPANY LTD (IL) | 2011-05-05 | — | — | WO | disclosed |
| EP-2292589-A1 | Novel multifunctional peptidase inhibitors, especially for medical use | IMTM GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2178527-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GmbH (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | IMTM GMBH (DE) | 2009-05-14 | — | — | US | disclosed |
| WO-2009024348-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1948627-A1 | NOVEL DUAL PEPTIDASE INHIBITORS AS PRODRUGS FOR THE THERAPY OF INFLAMMATORY AND OTHER DISORDERS | IMTM GmbH (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007057128-A1 | NOVEL DUAL PEPTIDASE INHIBITORS AS PRODRUGS FOR THE THERAPY OF INFLAMMATORY AND OTHER DISORDERS | IMTM GMBH (DE) | 2007-05-24 | — | — | WO | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | WEE1, WEE2, NME1 | CYP1A2 3059/4885KDM4E 420/4885GPR3 2861/4885 |
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | ANPEP, DNPEP, RNPEP | CYP1A2 2329/4885KDM4E 2238/4885GPR3 2737/4885 |
| US-20160106849-A1 | FORMULATIONS OF PHENYL URACIL COMPOUNDS | UNG, UMPS, TYMP | CYP1A2 1091/4885KDM4E 1166/4885GPR3 4306/4885 |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | CYP1A2 1119/4885KDM4E 3001/4885GPR3 2072/4885 |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CYP1A2 4286/4885KDM4E 2326/4885GPR3 4262/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | CYP1A2 1126/4885KDM4E 3461/4885GPR3 3026/4885 |
| US-20160158377-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | CYP1A2 4635/4885KDM4E 1090/4885GPR3 3749/4885 |
| US-20090124667-A1 | Novel Dual-Use Peptidase Inhibitors as Prodrugs for a Therapy of Inflammatory and Other Diseases | CTSL, DAO, PEPD | CYP1A2 285/4885KDM4E 2890/4885GPR3 1684/4885 |
| US-20150191437-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CYP1A2 673/4885KDM4E 3729/4885GPR3 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.